{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:28Z","timestamp":1788926788248,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03318-2","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:26:33Z","timestamp":1787203593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-2631","authenticated-orcid":false,"given":"Akhil","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-8650","authenticated-orcid":false,"given":"Bipinesh","family":"Sansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-5436","authenticated-orcid":false,"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1838-7097","authenticated-orcid":false,"given":"Bal Krishna","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0126-0195","authenticated-orcid":false,"given":"Archi","family":"Rungta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3825-3463","authenticated-orcid":false,"given":"Shreya","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-9555","authenticated-orcid":false,"given":"Minit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-5799","authenticated-orcid":false,"given":"Nandini","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omshree","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-0189","authenticated-orcid":false,"given":"Pratik","family":"Chandrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Choughule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"19","key":"3318_CR1","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1002\/cam4.4739","volume":"11","author":"H Chen","year":"2022","unstructured":"Chen H, Huang D, Lin G, et al. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-mutant non-small cell lung cancer. Cancer Med. 2022;11(19):3581\u201392. https:\/\/doi.org\/10.1002\/cam4.4739.","journal-title":"Cancer Med"},{"key":"3318_CR2","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3332\/ecancer.2024.1674","volume":"18","author":"V Noronha","year":"2024","unstructured":"Noronha V, Sarkar L, Patil V, et al. Clinical characteristics, outcomes and prognostic factors in KRAS-mutant lung cancers: experience from a tertiary cancer center in India. Ecancermedicalscience. 2024;18:1674. https:\/\/doi.org\/10.3332\/ecancer.2024.1674.","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"3318_CR3","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/j.cllc.2025.02.001","volume":"26","author":"M Shah","year":"2025","unstructured":"Shah M, Noronha V, Patil V, et al. Genomic profiling of driver gene alterations in NSCLC, patterns of treatment and survival outcomes: a single-center experience of >\u20091200 patients. Clin Lung Cancer. 2025;26(4):e270\u201383. https:\/\/doi.org\/10.1016\/j.cllc.2025.02.001.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"3318_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4103\/ijc.ijc_210_24","volume":"61","author":"V Noronha","year":"2024","unstructured":"Noronha V, Sarkar L, Patil V, et al. Real-world outcomes and treatment sequencing in KRAS-mutant NSCLC from India. Indian J Cancer. 2024;61(3):458\u201367. https:\/\/doi.org\/10.4103\/ijc.ijc_210_24.","journal-title":"Indian J Cancer"},{"key":"3318_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41417-024-00778-4","volume":"31","author":"Y Tang","year":"2024","unstructured":"Tang Y, Pu X, Yuan X, et al. Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential. Cancer Gene Ther. 2024;31:961\u20139. https:\/\/doi.org\/10.1038\/s41417-024-00778-4.","journal-title":"Cancer Gene Ther"},{"key":"3318_CR6","doi-asserted-by":"publisher","first-page":"1611580","DOI":"10.3389\/pore.2023.1611580","volume":"29","author":"J Moldvay","year":"2024","unstructured":"Moldvay J, T\u00edm\u00e1r J, Kiss A, et al. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges. Pathol Oncol Res. 2024;29:1611580. https:\/\/doi.org\/10.3389\/pore.2023.1611580.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"3318_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-022-00709-3","volume":"20","author":"KC Arbour","year":"2023","unstructured":"Arbour KC, Camidge DR, Spira AI, et al. Targeting KRAS mutations in NSCLC: clinical progress and challenges. Nat Rev Clin Oncol. 2023;20(1):37\u201353. https:\/\/doi.org\/10.1038\/s41571-022-00709-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3318_CR8","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/j.cllc.2023.12.009","volume":"25","author":"C Aggarwal","year":"2024","unstructured":"Aggarwal C, Liu SV, Papadimitrakopoulou V, et al. Clinical development of KRAS G12C inhibitors in NSCLC. Clin Lung Cancer. 2024;25(3):e134\u201347. https:\/\/doi.org\/10.1016\/j.cllc.2023.12.009.","journal-title":"Clin Lung Cancer"},{"key":"3318_CR9","doi-asserted-by":"publisher","first-page":"1385592","DOI":"10.3389\/fphar.2024.1385592","volume":"15","author":"G Padmaja","year":"2024","unstructured":"Padmaja G, Rao S, Kulkarni P, et al. Cost-effectiveness of molecular testing and targeted therapy for NSCLC in low- and middle-income settings. Front Pharmacol. 2024;15:1385592. https:\/\/doi.org\/10.3389\/fphar.2024.1385592.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3318_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/1078-0432.CCR-23-2122","volume":"30","author":"T Koga","year":"2024","unstructured":"Koga T, Suda K, Fujino T, et al. Liquid biopsy-based detection of KRAS mutations: clinical applications and challenges. Clin Cancer Res. 2024;30(6):1340\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2122.","journal-title":"Clin Cancer Res"},{"issue":"7781","key":"3318_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323. https:\/\/doi.org\/10.1038\/s41586-019-1694-1.","journal-title":"Nature"},{"issue":"1","key":"3318_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, et al. The KRAS G12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers. Cancer Discov. 2020;10(1):54\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1167.","journal-title":"Cancer Discov"},{"issue":"13","key":"3318_CR13","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.0c00506","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell JB, Fischer JP, Baer BR, et al. Identification of MRTX849, a covalent KRAS G12C inhibitor for cancer treatment. J Med Chem. 2020;63(13):6679\u201393. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00506.","journal-title":"J Med Chem"},{"issue":"25","key":"3318_CR14","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med"},{"issue":"3","key":"3318_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(22)00791-9","volume":"24","author":"SV Liu","year":"2023","unstructured":"Liu SV, Johnson ML, Awad MM, et al. CodeBreaK 200: Sotorasib versus docetaxel in previously treated NSCLC. Lancet Oncol. 2023;24(3):229\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(22)00791-9.","journal-title":"Lancet Oncol"},{"key":"3318_CR16","doi-asserted-by":"publisher","first-page":"S1309","DOI":"10.1016\/j.annonc.2023.08.1003","volume":"34","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Theelen WS, Jotte R, et al. KRYSTAL-7: efficacy and safety of adagrasib with pembrolizumab in treatment-na\u00efve KRASG12C NSCLC. Ann Oncol. 2023;34:S1309\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.1003.","journal-title":"Ann Oncol"},{"issue":"23","key":"3318_CR17","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","volume":"40","author":"SH Ou","year":"2022","unstructured":"Ou SH, J\u00e4nne PA, Leal TA, et al. First-in-human phase I\/IB study of adagrasib (MRTX849) in advanced KRAS G12C solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530\u20138. https:\/\/doi.org\/10.1200\/JCO.21.02752.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3318_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2208470","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2208470.","journal-title":"N Engl J Med"},{"issue":"18suppl","key":"3318_CR19","doi-asserted-by":"publisher","first-page":"LBA9001","DOI":"10.1200\/JCO.2025.43.18_suppl.LBA9001","volume":"43","author":"MG Fakih","year":"2025","unstructured":"Fakih MG, Tu H, Hsu H, et al. Clinical activity of Olomorasib, a next-generation KRAS G12C inhibitor. J Clin Oncol. 2025;43(18suppl):LBA9001. https:\/\/doi.org\/10.1200\/JCO.2025.43.18_suppl.LBA9001.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3318_CR20","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jtho.2025.08.102","volume":"20","author":"ML Johnson","year":"2025","unstructured":"Johnson ML, Mateos LL, Yamada T, et al. MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. J Thorac Oncol. 2025;20(10):S59. https:\/\/doi.org\/10.1016\/j.jtho.2025.08.102.","journal-title":"J Thorac Oncol"},{"key":"3318_CR21","unstructured":"Eli Lilly and Company. Lilly\u2019s Olomorasib receives Breakthrough Therapy designation. PR Newswire September 4, 2025."},{"issue":"1","key":"3318_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-24-2102","volume":"31","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Spira AI, Rybkin II, et al. Future landscape of KRAS G12C inhibitors in lung cancer therapy. Clin Cancer Res. 2025;31(1):21\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2102.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3318_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41573-024-00652-0","volume":"24","author":"SV Liu","year":"2025","unstructured":"Liu SV, Sabari JK, Gadgeel S, et al. Future prospects for KRAS G12C inhibition: combination therapy and next-generation compounds. Nat Rev Drug Discov. 2025;24(2):112\u201328. https:\/\/doi.org\/10.1038\/s41573-024-00652-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3318_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41573-024-00651-1","volume":"24","author":"BT Li","year":"2025","unstructured":"Li BT, Sabari JK, Velcheti V, et al. Next-generation KRAS inhibitors in clinical development. Nat Rev Drug Discov. 2025;24(1):15\u201333. https:\/\/doi.org\/10.1038\/s41573-024-00651-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"3318_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41589-022-01026-8","volume":"18","author":"JD Vasta","year":"2022","unstructured":"Vasta JD, Peacock DM, Zheng N, et al. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Nat Chem Biol. 2022;18(8):890\u20138. https:\/\/doi.org\/10.1038\/s41589-022-01026-8.","journal-title":"Nat Chem Biol"},{"key":"3318_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","volume":"8","author":"T Yoshinari","year":"2025","unstructured":"Yoshinari T, Nagashima T, Ishioka H, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025;8:254. https:\/\/doi.org\/10.1038\/s42004-025-01662-4.","journal-title":"Commun Chem"},{"issue":"4","key":"3318_CR27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-1971","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei D, Wang L, Zuo X, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res. 2024;30(4):655\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1971.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3318_CR28","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41467-023-37245-2","volume":"14","author":"MH Hofmann","year":"2023","unstructured":"Hofmann MH, Gmachl M, Ramharter J, et al. Overcoming adaptive feedback with SOS1 inhibitors in KRAS G12C\u2013driven cancers. Nat Commun. 2023;14(1):1785. https:\/\/doi.org\/10.1038\/s41467-023-37245-2.","journal-title":"Nat Commun"},{"key":"3318_CR29","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO-24-02026","volume":"43","author":"F Pietrantonio","year":"2025","unstructured":"Pietrantonio F, Antoniotti C, Fakih M, et al. CodeBreaK 300: sotorasib plus panitumumab in KRAS G12C colorectal cancer. J Clin Oncol. 2025;43:2147\u201354. https:\/\/doi.org\/10.1200\/JCO-24-02026.","journal-title":"J Clin Oncol"},{"issue":"25","key":"3318_CR30","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021;384(25):2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"issue":"7886","key":"3318_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS G12C inhibition. Nature. 2021;599(7886):679\u201383. https:\/\/doi.org\/10.1038\/s41586-021-04065-2.","journal-title":"Nature"},{"issue":"7904","key":"3318_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-022-04563-4","volume":"604","author":"N Tanaka","year":"2022","unstructured":"Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance mechanisms to KRAS G12C inhibition in lung cancer. Nature. 2022;604(7904):112\u201320. https:\/\/doi.org\/10.1038\/s41586-022-04563-4.","journal-title":"Nature"},{"issue":"7","key":"3318_CR33","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-23-2049","volume":"30","author":"N Chen","year":"2024","unstructured":"Chen N, Zhang Y, Li J, et al. MET amplification as a mechanism of resistance to KRAS G12C inhibition. Clin Cancer Res. 2024;30(7):1341\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2049.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3318_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41591-024-02813-8","volume":"30","author":"Y Jia","year":"2024","unstructured":"Jia Y, Wang T, Lin H, et al. MET-driven bypass signaling mediates resistance to KRAS inhibition in NSCLC. Nat Med. 2024;30(8):1392\u2013402. https:\/\/doi.org\/10.1038\/s41591-024-02813-8.","journal-title":"Nat Med"},{"issue":"9","key":"3318_CR35","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/2159-8290.CD-24-0031","volume":"14","author":"DA Cross","year":"2024","unstructured":"Cross DA, Chen M, Yang H, et al. EGFR activation contributes to KRAS inhibitor resistance. Cancer Discov. 2024;14(9):1897\u2013909. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0031.","journal-title":"Cancer Discov"},{"issue":"2","key":"3318_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12094-023-03205-x","volume":"26","author":"C Zhou","year":"2024","unstructured":"Zhou C, Hu X, Wang Z, et al. Emerging combination strategies for KRAS G12C\u2013mutant NSCLC. Clin Transl Oncol. 2024;26(2):211\u201325. https:\/\/doi.org\/10.1007\/s12094-023-03205-x.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"3318_CR37","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1158\/0008-5472.CAN-23-0844","volume":"84","author":"CC Ho","year":"2024","unstructured":"Ho CC, Chang YC, Lin CY, et al. Combination KRAS inhibition and SHP2 blockade in resistant NSCLC. Cancer Res. 2024;84(4):1104\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0844.","journal-title":"Cancer Res"},{"issue":"5","key":"3318_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41568-024-00615-5","volume":"24","author":"T Wang","year":"2024","unstructured":"Wang T, Zhao J, Zhang H, et al. Resistance mechanisms to KRAS inhibition and novel therapeutic targets. Nat Rev Cancer. 2024;24(5):271\u201385. https:\/\/doi.org\/10.1038\/s41568-024-00615-5.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3318_CR39","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/cam4.3755","volume":"10","author":"V Noronha","year":"2021","unstructured":"Noronha V, Abraham G, Patil V, et al. Real-world data of immune checkpoint inhibitors in solid tumors from India. Cancer Med. 2021;10(5):1525\u201334. https:\/\/doi.org\/10.1002\/cam4.3755.","journal-title":"Cancer Med"},{"issue":"1","key":"3318_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1055\/s-0044-1793049","volume":"14","author":"A Kumar","year":"2024","unstructured":"Kumar A, Kapoor A, Noronha V, et al. Efficacy and safety of low-dose nivolumab in advanced solid tumors: a retrospective audit. South Asian J Cancer. 2024;14(1):70\u20136. https:\/\/doi.org\/10.1055\/s-0044-1793049.","journal-title":"South Asian J Cancer"},{"key":"3318_CR41","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41417-021-00383-9","volume":"875","author":"Y Zhao","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther 2022;29:875\u2013878. https:\/\/doi.org\/10.1038\/s41417-021-00383-9","journal-title":"Cancer Gene Therapy"},{"issue":"5","key":"3318_CR42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/0008-5472.CAN-24-0254","volume":"84","author":"Y Suh","year":"2024","unstructured":"Suh Y, Kim J, Park E, et al. Adaptive RTK-RAS pathway activation and KRAS amplification as resistance mechanisms. Cancer Res. 2024;84(5):1255\u201368. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0254.","journal-title":"Cancer Res"},{"issue":"8","key":"3318_CR43","doi-asserted-by":"publisher","first-page":"101125","DOI":"10.1016\/j.xcrm.2024.101125","volume":"5","author":"J Kim","year":"2024","unstructured":"Kim J, Lee H, Park S, et al. Downstream signaling adaptations and PI3K\u2013AKT pathway activation in KRAS G12C inhibitor resistance. Cell Rep Med. 2024;5(8):101125. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101125.","journal-title":"Cell Rep Med"},{"issue":"10","key":"3318_CR44","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1158\/0008-5472.CAN-24-0448","volume":"84","author":"J Zhou","year":"2024","unstructured":"Zhou J, Wang Y, Zhao H, et al. PTEN loss and PI3K activation as bypass mechanisms to KRAS inhibition. Cancer Res. 2024;84(10):2652\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0448.","journal-title":"Cancer Res"},{"issue":"7790","key":"3318_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, Der CJ, Cox AD, et al. Feedback activation of wild-type RAS limits the response to KRAS G12C inhibition. Nature. 2020;577(7790):421\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1884-x.","journal-title":"Nature"},{"issue":"7","key":"3318_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.25.00077","volume":"43","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, Ou SH, Rybkin II, et al. KRYSTAL-7: Adagrasib plus pembrolizumab for KRAS G12C-mutated NSCLC. J Clin Oncol. 2025;43(7):890\u2013902. https:\/\/doi.org\/10.1200\/JCO.25.00077.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3318_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-24-0376","volume":"15","author":"JK Sabari","year":"2025","unstructured":"Sabari JK, Velcheti V, Shimizu K, et al. Checkpoint inhibitor combinations with KRAS G12C inhibitors. Cancer Discov. 2025;15(1):34\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0376.","journal-title":"Cancer Discov"},{"issue":"5","key":"3318_CR48","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jtho.2025.02.001","volume":"20","author":"JK Sabari","year":"2025","unstructured":"Sabari JK, Liu SV, Gadgeel SM, et al. Immunotherapy plus KRAS G12C inhibitors: early-phase results and future directions. J Thorac Oncol. 2025;20(5):647\u201359. https:\/\/doi.org\/10.1016\/j.jtho.2025.02.001.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3318_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41568-024-00655-x","volume":"24","author":"JJ Lin","year":"2024","unstructured":"Lin JJ, Tanaka N, Camidge DR, et al. Adaptive resistance and phenotypic plasticity in KRAS G12C\u2013mutant NSCLC. Nat Rev Cancer. 2024;24(9):589\u2013605. https:\/\/doi.org\/10.1038\/s41568-024-00655-x.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3318_CR50","doi-asserted-by":"publisher","first-page":"e010225","DOI":"10.1136\/jitc-2024-010225.56","volume":"12","author":"A Sheikh","year":"2024","unstructured":"Sheikh A, Patel J, Desai S, et al. Clinical efficacy of KRAS inhibitors across tumor types. J Immunother Cancer. 2024;12(6):e010225. https:\/\/doi.org\/10.1136\/jitc-2024-010225.56.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3318_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2025.02.003","volume":"33","author":"X Zhang","year":"2025","unstructured":"Zhang X, Li L, Chen Z, et al. Molecular determinants of sensitivity and resistance to KRAS inhibitors. Cancer Cell. 2025;33(3):255\u201373. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.003.","journal-title":"Cancer Cell"},{"key":"3318_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-025-00637-4","volume":"14","author":"Y Li","year":"2025","unstructured":"Li Y, Zhao J, Li Y, et al. New exploration of KRASG12D inhibitors and mechanisms of resistance. Exp Hematol Oncol. 2025;14:39. https:\/\/doi.org\/10.1186\/s40164-025-00637-4.","journal-title":"Exp Hematol Oncol"},{"key":"3318_CR53","doi-asserted-by":"publisher","first-page":"1509173","DOI":"10.3389\/fimmu.2025.1509173","volume":"16","author":"F Zhang","year":"2025","unstructured":"Zhang F, Wang B, Wu M, et al. Current status of KRAS G12C inhibitors in NSCLC and potential for combination with anti\u2013PD-(L)1 therapy. Front Immunol. 2025;16:1509173. https:\/\/doi.org\/10.3389\/fimmu.2025.1509173.","journal-title":"Front Immunol"},{"issue":"9","key":"3318_CR54","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41571-023-00798-8","volume":"20","author":"TSK Mok","year":"2023","unstructured":"Mok TSK, Wu YL, Kudaba I, et al. Immunotherapy in advanced NSCLC: insights from global trials. Nat Rev Clin Oncol. 2023;20(9):532\u201346. https:\/\/doi.org\/10.1038\/s41571-023-00798-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3318_CR55","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/crst.crst_64_19","volume":"2","author":"A Kapoor","year":"2019","unstructured":"Kapoor A, Noronha V, Patil VM, et al. Concomitant corticosteroids and immune checkpoint inhibitors: real-world experience. Cancer Res Stat Treat. 2019;2(2):204\u20138. https:\/\/doi.org\/10.4103\/crst.crst_64_19.","journal-title":"Cancer Res Stat Treat"},{"issue":"2","key":"3318_CR56","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jtho.2019.12.041","volume":"15","author":"SI Ou","year":"2020","unstructured":"Ou SI, Koczywas M, Ulahannan S, et al. A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial. J Thorac Oncol 2020;15(2):S15\u2013S16. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.041","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"3318_CR57","doi-asserted-by":"publisher","first-page":"e20201414","DOI":"10.1084\/jem.20201414","volume":"218","author":"C Fedele","year":"2021","unstructured":"Fedele C, Ran H, Diskin B, et al. SHP2 inhibition diminishes KRAS(G12C) cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021;218(1):e20201414. https:\/\/doi.org\/10.1084\/jem.20201414.","journal-title":"J Exp Med"},{"key":"3318_CR58","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41422-024-00990-9","volume":"34","author":"X Wang","year":"2024","unstructured":"Wang X, Wang W, Zou S, et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in advanced solid tumors. Cell Res. 2024;34:661\u20134. https:\/\/doi.org\/10.1038\/s41422-024-00990-9.","journal-title":"Cell Res"},{"issue":"2","key":"3318_CR59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/ijmio.ijmio_18_23","volume":"8","author":"A Kapoor","year":"2023","unstructured":"Kapoor A, Kapoor AR, Kumar A, et al. Molecular oncology and the role of artificial intelligence in advancing cancer treatment. Int J Mol Immuno Oncol. 2023;8(2):89\u201392. https:\/\/doi.org\/10.4103\/ijmio.ijmio_18_23.","journal-title":"Int J Mol Immuno Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03318-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:20:54Z","timestamp":1788924054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03318-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3318"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03318-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Akhil Kapoor Research Funding: AstraZeneca (Inst), Novartis (Inst), Lilly (Inst), Biocon (Inst), Bayer (Inst), Johnson & Johnson\/Janssen (Inst), BMS (Inst), Pfizer (Inst). Anuj Gupta Research Funding: AstraZeneca (Inst), Novartis (Inst), Lilly (Inst), Biocon (Inst), Bayer (Inst). Bipinesh Sansar Research Funding: AstraZeneca (Inst), Johnson & Johnson\/Janssen (Inst), BMS (Inst). Bal Krishna Mishra Research Funding: AstraZeneca (Inst), Pfizer (Inst). Vanita Noronha Research Funding: AstraZeneca (Inst), Merck (Inst), Novartis (Inst), Roche India (Inst), Johnson & Johnson\/Janssen (Inst), Nanobiotix (Inst)Travel, Accommodations, Expenses: ASCOKumar Prabhash Research Funding: Biocon (Inst), Dr Reddy\u2019s Laboratories (Inst), Fresenius Kabi (Inst), Alkem Laboratories (Inst), NATCO Pharma (Inst), BDR Pharmaceutics International (Inst), Roche (Inst), Aurigene Oncology Limited (Inst), Johnson and Johnson (Inst)No other potential conflicts of interest were reported.If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"251"}}